Welcome to our dedicated page for Madrigal Pharmac news (Ticker: MDGL), a resource for investors and traders seeking the latest updates and insights on Madrigal Pharmac stock.
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company centered on metabolic dysfunction-associated steatohepatitis (MASH), with its lead therapy Rezdiffra (resmetirom) and a growing pipeline of liver-directed treatments. The MDGL news feed on Stock Titan aggregates company announcements and third-party coverage so readers can follow how Madrigal’s clinical, regulatory, and commercial activities evolve over time.
News about Madrigal frequently highlights new clinical data from its Phase 3 MAESTRO program, including imaging, biomarker, and quality-of-life results in patients with MASH and compensated MASH cirrhosis (F4c). The company also issues updates on outcomes from major scientific meetings such as the American Association for the Study of Liver Diseases (AASLD) Liver Meeting and presentations at healthcare investment conferences.
Investors and healthcare observers will see regular press releases on Rezdiffra’s commercial performance, including product revenue, patient and prescriber adoption, and geographic expansion following regulatory approvals in the U.S. and Europe. Madrigal also reports on licensing transactions that expand its MASH pipeline, such as global agreements for an oral GLP-1 receptor agonist and ervogastat, a DGAT-2 inhibitor intended for combination use with Rezdiffra.
Additional news items cover corporate and capital structure developments disclosed via Form 8-K filings, including financing agreements, credit facilities, and governance matters such as annual meeting results and equity inducement awards under stock plans. For users tracking MDGL stock, this page offers a centralized view of Madrigal’s latest disclosures related to Rezdiffra, its broader MASH program, and key financial and strategic milestones. Bookmark this feed to monitor new data releases, regulatory and commercial updates, and pipeline progress that may influence the company’s long-term outlook.
Madrigal Pharmaceuticals (NASDAQ:MDGL) has secured an exclusive global license agreement with CSPC Pharmaceutical Group for SYH2086, a preclinical oral GLP-1 receptor agonist. The deal involves an upfront payment of $120 million and potential milestone payments up to $2 billion, plus royalties.
The agreement aligns with Madrigal's strategy to develop combination treatments for MASH (Metabolic dysfunction-Associated SteatoHepatitis), building upon their foundational therapy Rezdiffra™. Clinical development is planned to begin in first half of 2026. The combination aims to leverage GLP-1's weight loss benefits with Rezdiffra's fibrosis and lipid reduction capabilities in a once-daily oral formulation.
Madrigal Pharmaceuticals (NASDAQ:MDGL), a biopharmaceutical company specializing in treatments for metabolic dysfunction-associated steatohepatitis (MASH), has scheduled its second-quarter 2025 financial results release for August 5, 2025, before U.S. markets open.
The company will host a live webcast at 8:00 AM ET where management will discuss financial and operating results. Participants are advised to register 15 minutes before the webcast, which will be accessible through Madrigal's Investor Relations website. A replay will be available approximately two hours after the live event.
Madrigal Pharmaceuticals (NASDAQ:MDGL) has secured a $500 million senior secured credit facility from Blue Owl Capital managed funds. The non-dilutive financing includes a $350 million initial term loan at closing (partly used to refinance $115 million existing debt), a $150 million delayed draw term loan available through December 2027, and potential additional facilities up to $250 million.
The funding will primarily support MASH (metabolic dysfunction-associated steatohepatitis) pipeline expansion and strategic growth. The company highlighted strong U.S. launch momentum for Rezdiffra, with patent protection through 2044, and an ongoing pivotal F4c outcomes trial.
Madrigal Pharmaceuticals (NASDAQ:MDGL), a biopharmaceutical company focused on MASH therapeutics, announced equity inducement awards to 30 new non-executive employees under its 2025 Inducement Plan. The awards include options to purchase 5,675 shares and 19,863 time-based restricted stock units.
The options were granted at exercise prices of $300.16 (July 1) and $311.14 (July 15) per share. Options vest 25% after one year, followed by 6.25% quarterly thereafter. Restricted stock units vest in four equal annual installments. All awards require continued employment for vesting.
Madrigal Pharmaceuticals (NASDAQ:MDGL) has received a Notice of Allowance from the USPTO for a new patent covering Rezdiffra™ (resmetirom), their FDA-approved treatment for adults with noncirrhotic MASH with moderate to advanced liver fibrosis.
The patent, which will be listed in the FDA's Orange Book, provides protection through September 30, 2044. It specifically covers Rezdiffra's commercial weight-threshold dosing regimen as prescribed in the FDA-approved label. This development strengthens Madrigal's market position as the provider of the first and only FDA-approved treatment for MASH (also known as NASH).
Among patients with clinically significant portal hypertension (CSPH) at baseline, 65% moved to lower risk categories by year two. The study showed a statistically significant mean reduction of 6.7 kPa in liver stiffness, with 51% of patients achieving ≥25% improvement.
Notable outcomes include 35% of patients achieving liver stiffness measurements consistent with F3 fibrosis, suggesting cirrhosis reversal. The drug was well-tolerated, with common side effects including diarrhea, COVID-19, and nausea. The results support the ongoing Phase 3 MAESTRO-NASH OUTCOMES trial of Rezdiffra in compensated MASH cirrhosis.